Bortezomib
Key facts
| Invented name |
Velcade
|
| Active substance |
bortezomib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/78/2008
|
| PIP number |
Bortezomib
|
| Pharmaceutical form(s) |
Powder of solution for injection
|
| Condition(s) / indication(s) |
Treatment of mantle cell lymphoma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Janssen-Cilag International NV
E-mail: sglawe@jacde.jnj.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|